Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Asian Markets

Arafura Secures Final Funding Tranche for Rare Earths Project

Felix Baarz by Felix Baarz
December 13, 2025
in Asian Markets, Commodities, Penny Stocks
0
Arafura Stock
0
SHARES
31
VIEWS
Share on FacebookShare on Twitter

The Australian rare earths developer Arafura Rare Earths has successfully closed a major equity raising, marking one of the largest capital injections in the nation’s resources sector for 2025. The move brings the company a significant step closer to a final investment decision for its flagship Nolans project.

Equity Placement and Shareholder Dilution

The capital raise was executed in two tranches, culminating in a total of approximately AUD $475 million. The final institutional placement, completed on December 12, involved the issue of 1.26 billion new shares at AUD $0.28 each, raising AUD $351.6 million. Combined with the first tranche, the company has issued roughly 1.7 billion new shares, resulting in considerable dilution for existing shareholders.

A concurrent share purchase plan for retail investors, which closed on December 9, aimed to raise up to AUD $50 million. The results of this offering are scheduled for release on December 15.

Major Backer Reinforces Position

The institutional placement attracted strong interest, with Hancock Prospecting emerging as the cornerstone investor. Already the largest shareholder, Hancock contributed approximately AUD $125 million to the raise. Shareholders had previously approved the second tranche with an 87.9% vote at a meeting held on December 5.

Debt Package Fully Structured

On the debt financing side, Arafura has secured a complete package. Export Development Canada confirmed on December 1 the extension of its credit approval for USD $300 million, maintaining the original terms agreed in May 2024. All other consortium lenders have also upheld their commitments.

The total senior debt facility stands at USD $775 million, with an additional USD $80 million cost overrun facility. The lending consortium includes Export Finance Australia, the Northern Australia Infrastructure Facility, KEXIM, and commercial banks KfW IPEX-Bank, Commonwealth Bank, and ING.

Should investors sell immediately? Or is it worth buying Arafura?

Path to Final Investment Decision

With the equity raising nearly complete, one final piece remains. The company is awaiting a credit guarantee from Germany’s Euler Hermes for a tranche worth approximately AUD $115 million. Upon securing this, Arafura anticipates making its final investment decision in the first quarter of 2026.

Construction on the Nolans project is expected to begin 3 to 6 months after that decision, targeting first production for 2028 or 2029.

The Nolans Project at a Glance

Located about 135 kilometers north of Alice Springs in the Northern Territory, the Nolans project is poised to become one of Australia’s first integrated rare earths processing facilities.

  • Project Life: 38 years
  • Annual Production: 4,440 tonnes of neodymium-praseodymium (NdPr) oxide
  • Capital Cost: USD $1,044 million to first production
  • Post-Tax NPV8: USD $1,729 million (base case)
  • Post-Tax IRR: 17.2%

The operation is designed to supply approximately 4% of global NdPr demand. These materials are critical components for the permanent magnets used in electric vehicle motors and wind turbines.

The significant share issuance has weighed on the stock, with the issue price of AUD $0.28 sitting well below previous trading levels—a typical discount for large placements but a point of pressure for existing holders. The company’s market capitalization currently fluctuates between AUD $760 and AUD $860 million.

Ad

Arafura Stock: Buy or Sell?! New Arafura Analysis from February 7 delivers the answer:

The latest Arafura figures speak for themselves: Urgent action needed for Arafura investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 7.

Arafura: Buy or sell? Read more here...

Tags: Arafura
Felix Baarz

Felix Baarz

My name is Felix Baarz, and I look back on over fifteen years of experience as a business journalist. I have always been fascinated by the mechanisms and dynamics of global financial markets as well as the complex economic and political interconnections that shape our world. With this passion, I have made a name for myself as an expert on international financial markets and dedicate myself with great commitment to making even the most complex topics understandable and accessible to my readers. My roots lie in Cologne, where I was born and raised. Early on, my curiosity about economic topics and international developments sparked my interest in journalism. After completing my studies, I began my career as a business editor at a respected German trade publication. Here I laid the foundation for my professional career, but my curiosity soon drew me out into the wider world. A turning point in my life was moving to New York, where I lived for six years and gained insight into leading media houses. In this vibrant metropolis, I was able to report firsthand from the heart of the global financial world. From daily developments on Wall Street to major economic policy decisions that make waves worldwide, I had the opportunity to write about central topics that move people and markets alike. This time shaped my perspective and sharpened my view of global interconnections.

Related Posts

Tellurian Stock
Energy & Oil

Tellurian Acquisition Finalized as Woodside Takes Control

February 6, 2026
Schnitzer Steel Industries Stock
Analysis

Navigating Change: Schnitzer Steel’s Digital and Structural Evolution

February 6, 2026
Xiaobai Maimai Stock
Asian Markets

Akso Health Group Pivots to Oncology with Global Patient Initiative

February 6, 2026
Next Post
Northwest Pipe Stock

Northwest Pipe Shares Present a Contradictory Picture

Glaukos Stock

Divergent Signals Emerge for Glaukos Stock

Uranium Energy Stock

Uranium Energy's Strategic Pivot: From Exploration to Active Production

Recommended

CRWD stock news

Tower Research Capital LLC TRC Demonstrates Unwavering Confidence in CrowdStrike Holdings as Cybersecurity Leader

2 years ago
Efficiently Reporting an Absence on WalmartOne: A Step-by-Step Guide for Employees

Beacon Announces Interim Chief Financial Officer

2 years ago

Alaska Airlines Boeing 737 Investigation Missing Bolts and Safety Measures

2 years ago

Impressive Financial Performance for Kiniksa Pharmaceuticals

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

Diginex Enters Critical Implementation Phase Following Strategic Moves

Deluxe Stock Gains Momentum on Successful Fintech Transition

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Trending

Universal Insurance Stock
Analysis

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

by Rodolfo Hanigan
February 7, 2026
0

Universal Insurance Holdings has reaffirmed its commitment to shareholder returns, declaring its regular quarterly dividend despite a...

Embecta Stock

Embecta’s Q1 Performance Outpaces Analyst Forecasts

February 7, 2026
Camping World Stock

Camping World’s New Leadership Faces First Major Test

February 7, 2026
Viking Therapeutics Stock

Viking Therapeutics: Upcoming Financial Report to Guide Investor Sentiment

February 7, 2026
Diginex Stock

Diginex Enters Critical Implementation Phase Following Strategic Moves

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds
  • Embecta’s Q1 Performance Outpaces Analyst Forecasts
  • Camping World’s New Leadership Faces First Major Test

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com